- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800941
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension (HEMA-HTP)
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study.
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their low level of proof in the PHT. Last but not least, anticoagulants are known to be the principal cause of iatrogenic hospitalization (major bleeding).
In this study, patients are all followed during one year, to determine the annual frequency of major bleedings (according to the International Society on Thrombosis and Haemostasis (ISTH) international definition). Each event notified is validated by an independent committee for clinical events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their low level of proof in the PHT. Last but not least, anticoagulants are known to be the principal cause of iatrogenic hospitalization (bleeding).
The only one study scaling the tolerance of anticoagulants for this population found major hemorrhagic levels discording with the clinical practice : really high for connectives associated to pulmonary arterial hypertension (PAHT), and lower in "simple" pulmonary embolism in CTE-PHT. These discoveries could belong to methodological failures of this study: a retrospective, monocentric one, without adjudication of events by an independent committee. Furthermore, there were no information about the existence of a validated indication for anticoagulant treatments.
Patients are all followed during one year, to determine the annual frequency of major bleedings (according to the International Society on Thrombosis and Haemostasis (ISTH) international definition). Each event notified is validated by an independent committee for clinical events.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Laurent Bertoletti, PhD
- Phone Number: +33 04.77.82.91.21
- Email: laurent.bertoletti@chu-st-etienne.fr
Study Contact Backup
- Name: Carine Labruyere, CRA
- Phone Number: +33 04 77 12 04 69
- Email: carine.labruyere@chu-st-etienne.fr
Study Locations
-
-
-
Clermont-Ferrand, France
- Recruiting
- CHU Clermont-Ferrand
-
Principal Investigator:
- Claire DAUPHIN, MD
-
Sub-Investigator:
- Romain TRESORIER, MD
-
Grenoble, France, 38100
- Recruiting
- CHU de Grenoble
-
Sub-Investigator:
- Hélène BOUVAIST, MD
-
Principal Investigator:
- Christophe Pison, MD
-
Lyon, France, 69002
- Recruiting
- Hospices Civils de Lyon
-
Sub-Investigator:
- Clément DEUDON, MD
-
Sub-Investigator:
- Julie TRACLET, MD
-
Sub-Investigator:
- Ségolène Turquier, MD
-
Sub-Investigator:
- Kais Ahmad, MD
-
Saint-Etienne, France, 42055
- Recruiting
- CHU de Saint-Etienne
-
Sub-Investigator:
- Jean-Baptiste GAULTIER, MD
-
Contact:
- Laurent Bertoletti, PhD
- Phone Number: +33 04 77 82 91 21
- Email: laurent.bertoletti@chu-st-etienne.fr
-
Principal Investigator:
- Laurent Bertoletti, PhD
-
Sub-Investigator:
- Elodie DE MAGALHAES, MD
-
Sub-Investigator:
- Judith Catella, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient insured or entitled to a social security scheme;
- Patient with confirmed pulmonary hypertension;
- Pulmonary hypertension among the following etiological diagnosis: idiopathic PAH, PAH associated with appetite suppressants, PAH associated with connective, or Chronic Thrombo-embolism Pulmonary Hypertension;
- Patients receiving oral anticoagulants.
Exclusion Criteria:
- Impossible following;
- Bleeding at baseline;
- Life expectancy of less than 3 months;
- Pulmonary hypertension in Group 2, Group 3 (in the absence of associated pulmonary embolism) and Group 5 (in the absence of associated pulmonary embolism).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Oral anticoagulant treatment
Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice.
Patients have follow-up at 3, 6 and 12 months.
|
The treatment is delivered according to the usual practice.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of major bleeding (according to the International Society on Thrombosis and Haemostasis definition)
Time Frame: 1 year
|
Major bleedings (according to the International Society on Thrombosis and Haemostasis definition) will be notified during one year under oral anticoagulant treatment.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of clinically relevant bleedings
Time Frame: 1 year
|
Clinically relevant bleedings (major and non major ones) will be notified during one year under oral anticoagulant treatment.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Laurent Bertoletti, PhD, CHU de Saint-Etienne
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1608037
- 2016-001608-41 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Oral anticoagulant treatment
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Ajou University School of MedicineActive, not recruitingObesity | Atrial Fibrillation | Prognosis | AnticoagulantsKorea, Republic of
-
InCor Heart InstituteRecruiting
-
Yonsei UniversityUnknownAtrial FibrillationKorea, Republic of
-
Azienda Ospedaliera Città della Salute e della...UnknownAtrial Fibrillation | Oral Anticoagulants | Ischem Heart Disease | Primary Coronay InterventionItaly
-
Suleyman Demirel UniversityActive, not recruitingAtrial Fibrillation | Cardioversion | Cerebrovascular StrokeTurkey
-
Peking Union Medical College HospitalRecruitingVenous Thromboembolism | Pulmonary Embolism | Anticoagulant-induced BleedingChina
-
Assiut UniversityRecruitingObesity ParadoxEgypt
-
Danderyd HospitalKarolinska InstitutetTerminatedAtrial Fibrillation | Pulmonary EmbolismSweden